{"filing":{"accession_number":"0001724521-26-000050","cik":"0001724521","ticker":"RCUS","company_name":"Arcus Biosciences, Inc.","form":"8-K","filing_date":"2026-10-23","report_date":"2026-10-21","primary_document":"rcus-20261021.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1724521/000172452126000050/rcus-20261021.htm"},"events":[{"id":37609,"run_id":34659,"accession_number":"0001724521-26-000050","anchor_item_number":"8.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Arcus Biosciences completed a public offering of 16,428,572 shares of common stock (including full exercise of the underwriters' option) at $17.50 per share, raising approximately $269.7 million in net proceeds. This is a material registered equity issuance that dilutes existing shareholders and represents a significant capital raise for the company.","company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","filing_date":"2026-10-23","form":"8-K","submitted_at":null,"items":[{"id":42376,"accession_number":"0001724521-26-000050","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Arcus Biosciences completed a public offering of 16,428,572 shares of common stock (including full exercise of the underwriters' option) at $17.50 per share, raising approximately $269.7 million in net proceeds. This is a material registered equity issuance that dilutes existing shareholders and represents a significant capital raise for the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T20:13:51.155121+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42376,"accession_number":"0001724521-26-000050","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Arcus Biosciences completed a public offering of 16,428,572 shares of common stock (including full exercise of the underwriters' option) at $17.50 per share, raising approximately $269.7 million in net proceeds. This is a material registered equity issuance that dilutes existing shareholders and represents a significant capital raise for the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-10-23T20:13:51.155121+00:00","company_name":"Arcus Biosciences, Inc.","ticker":"RCUS","filing_date":"2026-10-23"}]}